Kaempferol Absorption and Pharmacokinetics Evaluation

This study is looking at how your body absorbs and uses Kaempferol, a natural compound found in many plants. We want to understand how much Kaempferol gets into your system and how long it stays there. You would take Kaempferol capsules once a day for 8 days. We'll collect blood and urine samples to measure Kaempferol levels and check for any changes in your body. This study is for healthy adults aged 18 to 70. We aim to enroll 120 participants. The study's status is currently unclear, so we don't know if it's actively recruiting yet.

Study design
This is an interventional study involving 120 healthy adult participants. It is designed to evaluate how the body absorbs and processes Kaempferol.
What's involved
You would take Kaempferol orally once daily for 8 days. This involves clinic visits, blood draws, urine collection, and follow-up assessments.
Compensation
Not stated in the trial record.
Follow-up
Your Kaempferol levels will be measured from the first dose through 24 hours after your final dose on Day 8.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07322406

Kaempferol Absorption and Pharmacokinetics Evaluation

Recruiting
NAAges 18–70InterventionalBasic science
University of Pittsburgh
~120 participants
Updated 2026-03-23 on ClinicalTrials.gov
What's tested:Kaempferol

At a glance

Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum plasma concentration (Cmax) of Kaempferol
Measured over From dosing on Day 1 through 24 hours after the final dose (Day 8)
+5 more outcomes measured
No Disease
Mitochondria Health
Longevity
Pharmacokinetics and Biological Absorption of Kaempferol in Healthy Adult
Healthy Volunteers

NCT07322406

Where you'd take part

This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolinastudy coordinator listed

    Not yet recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvaniastudy coordinator listed

    Recruiting

  • Weill Cornell Medicine

    New York, New Yorkstudy coordinator listed

    Not yet recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Afshin Beheshti, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Healthy volunteers as determined by medical history and screening assessment
Ability to understand the study procedures and provide informed consent
Willingness and ability to comply with all study procedures, including dietary restrictions, clinic visits, blood draws, urine collection, and follow-up assessments
Willingness to abstain from restricted foods, beverages, and supplements as specified in the study protocol during the study period

Exclusion

Known allergy or hypersensitivity to Kaempferol or related flavonoids
Pregnancy or breastfeeding
Presence of significant acute or chronic medical conditions that could increase risk or interfere with study outcomes, including but not limited to:
Active or chronic infections
Cancer
Cardiovascular disease
Neurological or neurodegenerative disorders
Metabolic or systemic inflammatory conditions
Use of prescription medications or supplements known to interfere with Kaempferol metabolism or pharmacokinetic assessment
Blood donation within 8 weeks prior to study enrollment
Participation in another interventional clinical study within a timeframe that could interfere with study results or participant safety
Any condition or circumstance that, in the judgment of the study investigator, would make participation unsafe or compromise data integrity
  • Maximum plasma concentration (Cmax) of KaempferolFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The maximum observed plasma concentration of Kaempferol following oral administration, calculated from serial plasma samples collected at predefined time points.

  • Time to maximum plasma concentration (Tmax) of KaempferolFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The time elapsed from oral administration of Kaempferol to the occurrence of the maximum observed plasma concentration (Cmax), determined from serial plasma sampling.

  • Area under the plasma concentration-time curve (AUC) of KaempferolFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The area under the plasma concentration-time curve of Kaempferol, calculated using noncompartmental methods to quantify overall systemic exposure following oral administration.

  • Plasma elimination half-life (t½) of KaempferolFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The terminal elimination half-life of Kaempferol in plasma, estimated from the terminal phase of the concentration-time curve following oral administration.

  • Apparent clearance of KaempferolFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The apparent systemic clearance of Kaempferol following oral administration, calculated using standard pharmacokinetic methods based on plasma concentration data.

  • Urinary excretion of Kaempferol and metabolitesFrom dosing on Day 1 through 24 hours after the final dose (Day 8)

    The cumulative amount of Kaempferol and its metabolites excreted in urine, determined from timed urine collections following oral administration.